Clinical Pharmacology & Biopharmaceutics
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 790
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Editor-in-Chief
Editor-in-Chief
Shufeng Zhou
Professor
Department of Pharmaceutical Sciences
University of South Florida
USA
Biography
Dr. Zhou is presently a Professor, Associate Dean of International Research, and Chair of the Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida. Professor Zhou completed his clinical training in China in 1989 and obtained his PhD in 2001 from the School of Medicine, the University of Auckland, New Zealand. Professor Zhou has published more than 330 peer-reviewed papers in various pharmacology and medical journals including New England Journal of Medicine, Cancer Research, Journal of Biological Chemistry, Clinical Pharmacology and Therapeutics, and Clinical Cancer Research. He has also published 16 books and book chapters and more than 200 conference abstracts. His work has been cited more than 4,500 times by other colleagues. He is involved in the development of more than 10 lead compounds. To date, he has trained 24 PhD students, 12 MSc/Honors students, and 14 postdoctoral staff. Dr. Zhou serves as an editor-in-chief or editor for Drug, Healthcare and Patient Safety, Drug Metabolism Letters, and Current Drug Metabolism and is the editorial board member of other 20 medical and pharmacological journals. Dr. Zhou has given more than 80 invited seminars/keynote presentations to a variety of academic institutes, government agencies, and high-profile international conferences.
Research Interest
Drug discovery, Drug metabolism, Drug transport, Pharmacogenomics, Nanomedicine, Herbal medicines, and Stem cells
Network
Editor-In-Chief
Koji Shimoke
Professor
Department of Life Science and Biotechnology
Kansai University
Japan
Biography
Dr. Koji Shimoke has received his PhD in Biological chemistry in Graduate school of Osaka University in 1998. Currently, he is working as an Associate Professor in at Laboratory of Neurobiology, Department of Life Science and Biotechnology, Kansai University, Japan. He has successfully completed his Administrative responsibilities as Lecturer at Laboratory of Neurobiology, Kansai University, Japan. He is a member of Society for Neuroscience, USA.
Research Interest
Neurotrophin-mediated anti-apoptotic mechanisms of cerebral neurons and PC12 cells
Intracellular signaling leading to neurite outgrowth and neural networks
Epigenetic regulations in cell survival and neurite outgrowth
Clinical basic research about HDAC inhibitors
Toxicological research about endocrine disrupting chemicals
Editor-In-Chief
Giuseppe Morgia
Professor
Department of Urology
University of Catania
Italy
Biography
Prof. Joseph Morgia was Director of the Urology Clinic of the University of Sassari from 1/11/01 to 30/11/06 and the School of Urology 27/11/01 to 30/11/06 from the same university. Director of the Department of Integrated Activities Special Surgery of the University of Sassari from 1/8/03 to 30/11/06. Director of the Urology Clinic of the University of Messina from 1/12/06 and School of Urology of the University from 09/01/07. Professor of Urology at the following Schools of specialization: General Surgery, Plastic and Reconstructive Surgery, Geriatrics, Internal Medicine, Oncology in different University of Catania, Messina and Sassari. He has participated since 1984, about 350 national and Urological Courses and Conferences internationaly, in many of whom was Speaker, Moderator or Operator (courses live surgery) at the invitation of the Scientific Committee. The activity consists of over 240 scientific publications in national journals and acts conferences and journals found on Medline and / or with impact factor. He has written 10 chapters in urology texts and two monographs. Prof. Morgia is President of the Sicilian-Calabrian Society of Urology, a member of the Italian Society of Urology, Andrology and Urology Oncology, European Society of Urology and the American Society of Urology and Rewiever of important journals International (European Urology, Urology Internationalis, International Journal of Sexual Medicine, etc.,) Member of the Board of the Educational Committee of the European Association Office of Urology. Coordinator and organizer of several multicenter studies, as President of several scientific meetings. Holder of a Department for Health Research Region of Sicily for 2007 on prostate cancer.
Research Interest
Urology, Prostate diseases
Network
Editor-In-Chief
Senior Scientist PPDM QP2 PHARMACOMETRICS
Merck Sharp & Dohme Corp.
New Jersey, United States
Biography
Ankur Sharma obtained his B. Pharm from University of Rajasthan, Jaipur, India and his MS in Pharmacology from Rajiv Gandhi Technical University, Bhopal, India. After his MS he worked as a Research Associate in pre-clinical pharmacology R&D department of Piramal Life Sciences in India. Ankur Sharma has received his Ph.D. in Pharmaceutical Sciences from The University of Oklahoma, Health Sciences Center, College of Pharmacy. He was an ORISE fellow in the Office of Generic Drugs of US FDA in Department of Quantitative Methods & Modeling. Currently he is serving as a Senior Scientist in Quantitative Pharmacology & Pharmacometrics Department of Merck. His most significant research contributions include utilizing quantitative approaches like physiologically based pharmacokinetic modeling, and PK/PD modeling for quantitative prediction of drug levels in tumors with a possibility of human scale-up to enable First-in-Human (FIH) dose selection in cancer patients, determining mechanistic strategies to overcome tumor-resistance in ovarian cancer, bioanalytical method development for analysis of anti-cancer drugs in human plasma, utilizing PBPK approaches for ocular drug translation from animal data to predict human ocular PK and PD, and developing prodrugs for NSAIDs for improved efficacy and safety.
Research Interest
Bioanalytical Method Development, PBPK Modeling, PK/PD modeling, Population Based PK Modeling, Cancer cell biology, Immunology.
Network
